For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: https://www.mycme.com/courses/copd-inflammation-exacerbations-your-questions-answered-10143 Summary Rejoin the conversation on COPD, inflammation, and new and emerging agents as two of our expert faculty come together to answer your top questions. Questions submitted from the recent Conversations in Primary Care live virtual symposia guide the discussion as we dig a bit deeper on type 2 inflammation, changes in COPD management, and new and emerging agents – including recently approved biologic agents – for COPD. Learning Objectives At the conclusion of this activity, participants should be better able to: Review the relationship between inflammation, exacerbation, and disease progression in COPD, noting different inflammatory endotypes of patients with COPD Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD and type 2 inflammation Integrate current guidelines with clinical data on new and emerging agents for the management of COPD, distinguishing patients with and without markers of type 2 inflammation This activity is accredited for CME/CE Credit The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology). For additional information about the accreditation of this program, please contact NACE at
[email protected] . Summary of Individual Disclosures Please review faculty and planner disclosures here . Disclosure of Commercial Support This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi. Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
